Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)

Martin W. Schoen; Kenneth R. Carson; Seth A. Eisen; Charles L. Bennett; Suhong Luo; Melissa A. Reimers; Eric M. Knoche; Alison L. Whitmer; Yan Yan; Bettina F. Drake; Kristen M. Sanfilippo

doi:10.1038/s41391-023-00680-4

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)

Martin W. Schoen^*, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche, Alison L. Whitmer, Yan Yan, Bettina F. Drake, Kristen M. Sanfilippo

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher’s internet portal on 14 September 2022 without open access.

Original language	English (US)
Pages (from-to)	811
Number of pages	1
Journal	Prostate Cancer and Prostatic Diseases
Volume	26
Issue number	4
DOIs	https://doi.org/10.1038/s41391-023-00680-4
State	Published - Dec 2023

ASJC Scopus subject areas

Urology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41391-023-00680-4

Fingerprint

Dive into the research topics of 'Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)'. Together they form a unique fingerprint.

Cite this

Schoen, M. W., Carson, K. R., Eisen, S. A., Bennett, C. L., Luo, S., Reimers, M. A., Knoche, E. M., Whitmer, A. L., Yan, Y., Drake, B. F., & Sanfilippo, K. M. (2023). Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5). Prostate Cancer and Prostatic Diseases, 26(4), 811. https://doi.org/10.1038/s41391-023-00680-4

Schoen, Martin W. ; Carson, Kenneth R. ; Eisen, Seth A. et al. / Correction to : Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5). In: Prostate Cancer and Prostatic Diseases. 2023 ; Vol. 26, No. 4. pp. 811.

@article{714ae2cc48274a5a81cbe2d2fa32f9ef,

title = "Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)",

abstract = "Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher{\textquoteright}s internet portal on 14 September 2022 without open access.",

author = "Schoen, {Martin W.} and Carson, {Kenneth R.} and Eisen, {Seth A.} and Bennett, {Charles L.} and Suhong Luo and Reimers, {Melissa A.} and Knoche, {Eric M.} and Whitmer, {Alison L.} and Yan Yan and Drake, {Bettina F.} and Sanfilippo, {Kristen M.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41391-023-00680-4",

language = "English (US)",

volume = "26",

pages = "811",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

number = "4",

}

Schoen, MW, Carson, KR, Eisen, SA, Bennett, CL, Luo, S, Reimers, MA, Knoche, EM, Whitmer, AL, Yan, Y, Drake, BF & Sanfilippo, KM 2023, 'Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)', Prostate Cancer and Prostatic Diseases, vol. 26, no. 4, pp. 811. https://doi.org/10.1038/s41391-023-00680-4

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5). / Schoen, Martin W.; Carson, Kenneth R.; Eisen, Seth A. et al.
In: Prostate Cancer and Prostatic Diseases, Vol. 26, No. 4, 12.2023, p. 811.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)

AU - Schoen, Martin W.

AU - Carson, Kenneth R.

AU - Eisen, Seth A.

AU - Bennett, Charles L.

AU - Luo, Suhong

AU - Reimers, Melissa A.

AU - Knoche, Eric M.

AU - Whitmer, Alison L.

AU - Yan, Yan

AU - Drake, Bettina F.

AU - Sanfilippo, Kristen M.

PY - 2023/12

Y1 - 2023/12

N2 - Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher’s internet portal on 14 September 2022 without open access.

AB - Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher’s internet portal on 14 September 2022 without open access.

UR - http://www.scopus.com/inward/record.url?scp=85160668756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160668756&partnerID=8YFLogxK

U2 - 10.1038/s41391-023-00680-4

DO - 10.1038/s41391-023-00680-4

M3 - Comment/debate

C2 - 37253974

AN - SCOPUS:85160668756

SN - 1365-7852

VL - 26

SP - 811

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 4

ER -

Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA et al. Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5). Prostate Cancer and Prostatic Diseases. 2023 Dec;26(4):811. doi: 10.1038/s41391-023-00680-4

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this